logo-loader
viewPharmaxis Ltd

Biotech companies will outline operational highlights at Proactive Biotech Webinar next Tuesday

The webinar will also be live-streamed on the Proactive YouTube channel, which can be viewed at any time following the presentations.

Pharmaxis Ltd -
Executives from Pharmaxis, Cynata and Recce will present

There is strong global interest in the work of biotech companies and next week's Proactive Biotech Webinar will feature a number of ASX-listed companies making strong progress in the field.

Presenting at the webinar on Tuesday, November 10, will be Pharmaxis Ltd (ASX:PXS) along with Cynata Therapeutics Ltd (ASX:CYP) and Recce Pharmaceuticals Ltd (ASX:RCE).

Each company will present for 12 minutes, followed by a 5-minute Q&A session.

The webinar will also be live-streamed on the Proactive YouTube channel, which can then be viewed at any time following the presentation.

Discussing operational highlights 

Company executives will outline recent operational highlights and upcoming plans.

Pharmaxis chief executive officer Gary Phillips (below) will outline the Australian pharmaceutical company's expertise in developing drugs for inflammatory and fibrotic diseases.

The company has this week reached the top biotech echelon with the US Food & Drug Administration (FDA) agency’s approval of its cystic fibrosis treatment Bronchitol® (mannitol) representing a transformational milestone.

Not many Australian companies can boast the gold standard of success in biotech – US FDA approval of a medicine it has researched and developed – with CEO Phillips saying this was a “transformational step”.

Cynata managing director Dr Ross Macdonald (below) plans to highlight the company's progress towards multiple clinical trials using its Cymerus™ mesenchymal stem cell (MSC) products.

Recce Pharmaceuticals chief executive officer James Graham (below) will summarise the company’s operational highlights for the September quarter and its pathway towards developing and commercialising a new class of Synthetic Anti-infectives.

Event details

  • Date: Tuesday, November 10
  • Time: 12pm Sydney time/ 9am Perth time
  • To register: follow this link  
  • Questions for the speakers can be submitted before and during the presentations by email to John Phillips at [email protected] or by text to 0431 597 771

Quick facts: Pharmaxis Ltd

Price: 0.098 AUD

ASX:PXS
Market: ASX
Market Cap: $38.92 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis CEO says US FDA approval for Bronchitol® is 'big day in company's...

Pharmaxis Ltd's (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) Gary Phillips speaks to Proactive's Andrew Scott following the news the US FDA has approved its cystic fibrosis treatment Bronchitol®. The milestone clears Bronchitol for sale in the US as an add‐on maintenance therapy to improve pulmonary...

on 2/11/20

2 min read